RATIONALE: The NF-E2 related factor 2 (Nrf2)-antioxidant response element (ARE) pathway is essential for protection against oxidative injury and inflammation including hyperoxia-induced acute lung injury. Microarray expression profiling revealed that lung peroxisome proliferator activated receptor gamma (PPARgamma) induction is suppressed in hyperoxia-susceptible Nrf2-deficient (Nrf2(-/-)) mice compared with wild-type (Nrf2(+/+)) mice. PPARgamma has pleiotropic beneficial effects including antiinflammation in multiple tissues. OBJECTIVES: We tested the hypothesis that PPARgamma is an important determinant of pulmonary responsivity to hyperoxia regulated by Nrf2. METHODS: A computational bioinformatic method was applied to screen potential AREs in the Pparg promoter for Nrf2 binding. The functional role of a potential ARE was investigated by in vitro promoter analysis. A role for PPARgamma in hyperoxia-induced acute lung injury was determined by temporal silencing of PPARgamma via intranasal delivery of PPARgamma-specific interference RNA and by administration of a PPARgamma ligand 15-deoxy-Delta(12,14)-prostaglandin J(2) in mice. MEASUREMENTS AND MAIN RESULTS: Deletion or site-directed mutagenesis of a potential ARE spanning -784/-764 sequence significantly attenuated hyperoxia-increased Pparg promoter activity in airway epithelial cells overexpressing Nrf2, indicating that the -784/-764 ARE is critical for Nrf2-regulated PPARgamma expression. Mice with decreased lung PPARgamma by specific interference RNA treatment had significantly augmented hyperoxia-induced pulmonary inflammation and injury. 15 Deoxy-Delta(12,14)-prostaglandin J(2) administration significantly reduced hyperoxia-induced lung inflammation and edema in Nrf2(+/+), but not in Nrf2(-/-) mice. CONCLUSIONS: Results indicate for the first time that Nrf2-driven PPARgamma induction has an essential protective role in pulmonary oxidant injury. Our observations provide new insights into the therapeutic potential of PPARgamma in airway oxidative inflammatory disorders.
RATIONALE: The NF-E2 related factor 2 (Nrf2)-antioxidant response element (ARE) pathway is essential for protection against oxidative injury and inflammation including hyperoxia-induced acute lung injury. Microarray expression profiling revealed that lung peroxisome proliferator activated receptor gamma (PPARgamma) induction is suppressed in hyperoxia-susceptible Nrf2-deficient (Nrf2(-/-)) mice compared with wild-type (Nrf2(+/+)) mice. PPARgamma has pleiotropic beneficial effects including antiinflammation in multiple tissues. OBJECTIVES: We tested the hypothesis that PPARgamma is an important determinant of pulmonary responsivity to hyperoxia regulated by Nrf2. METHODS: A computational bioinformatic method was applied to screen potential AREs in the Pparg promoter for Nrf2 binding. The functional role of a potential ARE was investigated by in vitro promoter analysis. A role for PPARgamma in hyperoxia-induced acute lung injury was determined by temporal silencing of PPARgamma via intranasal delivery of PPARgamma-specific interference RNA and by administration of a PPARgamma ligand 15-deoxy-Delta(12,14)-prostaglandin J(2) in mice. MEASUREMENTS AND MAIN RESULTS: Deletion or site-directed mutagenesis of a potential ARE spanning -784/-764 sequence significantly attenuated hyperoxia-increased Pparg promoter activity in airway epithelial cells overexpressing Nrf2, indicating that the -784/-764 ARE is critical for Nrf2-regulated PPARgamma expression. Mice with decreased lungPPARgamma by specific interference RNA treatment had significantly augmented hyperoxia-induced pulmonary inflammation and injury. 15 Deoxy-Delta(12,14)-prostaglandin J(2) administration significantly reduced hyperoxia-induced lung inflammation and edema in Nrf2(+/+), but not in Nrf2(-/-) mice. CONCLUSIONS: Results indicate for the first time that Nrf2-driven PPARgamma induction has an essential protective role in pulmonary oxidant injury. Our observations provide new insights into the therapeutic potential of PPARgamma in airway oxidative inflammatory disorders.
Authors: Xuting Wang; Daniel J Tomso; Brian N Chorley; Hye-Youn Cho; Vivian G Cheung; Steven R Kleeberger; Douglas A Bell Journal: Hum Mol Genet Date: 2007-04-04 Impact factor: 6.150
Authors: K Itoh; T Chiba; S Takahashi; T Ishii; K Igarashi; Y Katoh; T Oyake; N Hayashi; K Satoh; I Hatayama; M Yamamoto; Y Nabeshima Journal: Biochem Biophys Res Commun Date: 1997-07-18 Impact factor: 3.575
Authors: L Benayoun; S Letuve; A Druilhe; J Boczkowski; M C Dombret; P Mechighel; J Megret; G Leseche; M Aubier; M Pretolani Journal: Am J Respir Crit Care Med Date: 2001-10-15 Impact factor: 21.405
Authors: Yihong Wan; Alan Saghatelian; Ling-Wa Chong; Chun-Li Zhang; Benjamin F Cravatt; Ronald M Evans Journal: Genes Dev Date: 2007-07-24 Impact factor: 11.361
Authors: Diána Papp; Katalin Lenti; Dezső Módos; Dávid Fazekas; Zoltán Dúl; Dénes Türei; László Földvári-Nagy; Ruth Nussinov; Péter Csermely; Tamás Korcsmáros Journal: FEBS Lett Date: 2012-05-26 Impact factor: 4.124
Authors: Darcy J P Bates; Pamela K Smitherman; Alan J Townsend; S Bruce King; Charles S Morrow Journal: Biochemistry Date: 2011-08-17 Impact factor: 3.162
Authors: Samantha M Yeligar; Janine M Ward; Frank L Harris; Lou Ann S Brown; David M Guidot; Sushma K Cribbs Journal: AIDS Res Hum Retroviruses Date: 2017-04-24 Impact factor: 2.205
Authors: Brahmchetna Bedi; Nicholas M Maurice; Vincent T Ciavatta; K Sabrina Lynn; Zhihong Yuan; Samuel A Molina; Myungsoo Joo; William R Tyor; Joanna B Goldberg; Michael Koval; C Michael Hart; Ruxana T Sadikot Journal: FASEB J Date: 2017-04-25 Impact factor: 5.191
Authors: Jennifer L Nichols; Wesley Gladwell; Kirsten C Verhein; Hye-Youn Cho; Jürgen Wess; Oscar Suzuki; Tim Wiltshire; Steven R Kleeberger Journal: FASEB J Date: 2014-02-26 Impact factor: 5.191